Literature DB >> 9099830

Microdeletion 22q11 in complex cardiovascular malformations.

Y Mehraein1, C F Wippermann, I Michel-Behnke, T K Nhan Ngo, U Hillig, M Giersberg, U Aulepp, H Barth, B Fritz, H Rehder.   

Abstract

Besides DiGeorge, velocardiofacial and conotruncal anomaly face syndromes, some of the isolated congenital heart diseases have also been associated with a chromosomal deletion in 22q11. These disease entities, which had originally been considered to have a different genetic background, are now included in the CATCH-22 microdeletion complex. CATCH 22 is an acronym for cardiac defect, abnormal facies, thymic hypoplasia or aplasia and T-cell deficiency, cleft palate, hypoparathyroidism, and hypocalcemia. In the present study, we focused on the complex cardiovascular defects (CCVD) and screened 40 patients for a microdeletion of 22q11 by fluorescence in situ hybridization using the D22S75 DNA probe and for associated CATCH features. The patients were from genetic counseling (n = 15) or fetopathology (n = 3) of the Clinical Genetics Department in Marburg and from the Pediatric Cardiology Department (n = 22) in Mainz. Monosomy 22q11 was detected in 9 cases (= 22.5%). Familial transmission with one mildly affected parent and one affected sib each was proven in two cases. The CCVDs comprised complex conotruncal defects such as tetralogy of Fallot, double outlet right ventricle, transposition of great arteries and truncus arteriosus communis, or anomalies of the derivatives of the branchial arch arteries in association with a ventricular septal defect, including one case of atresia of the ductus arteriosus with pulmonary artery aneurysm and resulting in fetal hydrops. All 13 patients with a deletion of 22q11 showed at least one additional CATCH symptom. Most consistently, facial dysmorphy was apparent (92%), while hypocalcemia, mostly at threshold values, was present in 62% and thymic hypoplasia including borderline low T-lymphocyte numbers was observed in 41%. None of the patients presented with a cleft palate. A high intrafamilial variability in expression was also evident with respect to the CCVD. Our findings indicate that seemingly isolated complex cardiovascular defects associated with a 22q11 microdeletion most probably do not represent a distinct subgroup within the CATCH-22 complex but are syndromal in nature with extracardiac features that are often overlooked.

Entities:  

Mesh:

Year:  1997        PMID: 9099830     DOI: 10.1007/s004390050385

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  6 in total

1.  Truncus arteriosus communis in a midtrimester fetus: comparison of prenatal ultrasound and MRI with postmortem MRI and autopsy.

Authors:  Matthias R Mühler; Anett Rake; Michael Schwabe; Rabih Chaoui; Kay-Sven Heling; Christiane Planke; Alexander Lembcke; Thomas Fischer; Dietmar Kivelitz
Journal:  Eur Radiol       Date:  2004-10-06       Impact factor: 5.315

Review 2.  Phenotype of adults with the 22q11 deletion syndrome: A review.

Authors:  E Cohen; E W Chow; R Weksberg; A S Bassett
Journal:  Am J Med Genet       Date:  1999-10-08

3.  Prenatal diagnosis of truncus arteriosus using multiplanar display in 4D ultrasonography.

Authors:  Francesca Gotsch; Roberto Romero; Jimmy Espinoza; Juan Pedro Kusanovic; Offer Erez; Sonia Hassan; Lami Yeo
Journal:  J Matern Fetal Neonatal Med       Date:  2010-04

4.  A population study of chromosome 22q11 deletions in infancy.

Authors:  J Goodship; I Cross; J LiLing; C Wren
Journal:  Arch Dis Child       Date:  1998-10       Impact factor: 3.791

5.  Chromosome 22q11 deletion in patients with truncus arteriosus.

Authors:  D B McElhinney; D A Driscoll; B S Emanuel; E Goldmuntz
Journal:  Pediatr Cardiol       Date:  2003-09-04       Impact factor: 1.655

6.  Genetic analysis of chromosome 22q11.2 markers in congenital heart disease.

Authors:  Yi-Ru Shi; Kai-Sheng Hsieh; Jer-Yuarn Wu; Cheng-Chun Lee; Chang-Hai Tsai; Ming-Tseng Yu; Jeng-Sheng Chang; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.